152 related articles for article (PubMed ID: 3480081)
1. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.
Speth PA; Linssen PC; Boezeman JB; Wessels HM; Haanen C
Cancer Chemother Pharmacol; 1987; 20(4):305-10. PubMed ID: 3480081
[TBL] [Abstract][Full Text] [Related]
2. Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.
Speth PA; Linssen PC; Boezeman JB; Wessels HM; Haanen C
Cancer Chemother Pharmacol; 1987; 20(4):311-5. PubMed ID: 3690804
[TBL] [Abstract][Full Text] [Related]
3. Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).
Raijmakers R; Speth P; de Witte T; Linssen P; Wessels J; Haanen C
Br J Cancer; 1987 Aug; 56(2):123-6. PubMed ID: 3663464
[TBL] [Abstract][Full Text] [Related]
4. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion.
Speth PA; Linssen PC; Holdrinet RS; Haanen C
Clin Pharmacol Ther; 1987 Jun; 41(6):661-5. PubMed ID: 3581649
[TBL] [Abstract][Full Text] [Related]
5. In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells.
Speth PA; Raijmakers RA; Boezeman JB; Linssen PC; de Witte TJ; Wessels HM; Haanen C
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):667-74. PubMed ID: 3383969
[TBL] [Abstract][Full Text] [Related]
6. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.
Muller C; Chatelut E; Gualano V; De Forni M; Huguet F; Attal M; Canal P; Laurent G
Cancer Chemother Pharmacol; 1993; 32(5):379-84. PubMed ID: 8339389
[TBL] [Abstract][Full Text] [Related]
7. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
8. Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma.
Speth PA; Linssen PC; Beex LV; Boezeman JB; Haanen C
Cancer Chemother Pharmacol; 1986; 18(1):78-82. PubMed ID: 3463436
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
Cusack BJ; Young SP; Driskell J; Olson RD
Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
[TBL] [Abstract][Full Text] [Related]
11. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin.
Speth PA; van de Loo FA; Linssen PC; Wessels HM; Haanen C
Clin Pharmacol Ther; 1986 Dec; 40(6):643-9. PubMed ID: 3465490
[TBL] [Abstract][Full Text] [Related]
12. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM.
Solary E; Velay I; Chauffert B; Bidan JM; Caillot D; Dumas M; Guy H
Cancer; 1991 Oct; 68(8):1714-9. PubMed ID: 1913513
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.
Munck JN; Riggi M; Rougier P; Chabot GG; Ramirez LH; Zhao Z; Bognel C; Ardouin P; Herait P; Gouyette A
Cancer Res; 1993 Apr; 53(7):1550-4. PubMed ID: 8453622
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.
Mader RM; Zilg H; Schlappack O; Steger GG; Baur M; Greifenberg B; Heberle U; Dittrich C
Cancer Chemother Pharmacol; 1995; 37(1-2):91-6. PubMed ID: 7497603
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo.
Tapiero H; Munck JN; Fourcade A
Drugs Exp Clin Res; 1986; 12(1-3):257-64. PubMed ID: 3460752
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of vincristine infusion.
Jackson DV; Sethi VS; Spurr CL; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Castle MC
Cancer Treat Rep; 1981; 65(11-12):1043-8. PubMed ID: 7296550
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of adriamycin by bronchial artery infusion for non-small cell bronchogenic carcinoma].
Wang T; Yang H; Wang H
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):395-8. PubMed ID: 11810771
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
Miller AA; Schmidt CG
Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
[TBL] [Abstract][Full Text] [Related]
19. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
20. [Phase I-II study of hepatic intraarterial one-shot administration of adriamycin in patients with metastatic liver cancer].
Horikoshi N; Ogawa M; Tabata M; Inoue K; Mukaiyama T; Fukutani H; Hirano A; Mizunuma N; Itami S; Oohashi K
Gan To Kagaku Ryoho; 1991 May; 18(6):977-82. PubMed ID: 2029200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
